Microfluidic Qualitative Immunoassay

FREND™ COVID-19 Ag + Flu A&B

The FREND™ COVID-19 Ag + Flu A&B is a fluorescence immunoassay (FIA) for use with the FREND™ System.

 It is designed for the qualitative and simultaneous detection of the nucleocapsid protein of SARS-CoV-2 and Influenza A&B virus.

It measures directly from nasopharyngeal swab specimens.

  Instructions for use

Accurate result in 3 minutes!

With just simple steps of operation, FREND™ System supports quick decision-making.

Performance evaluation

Clinical agreement study

[COVID-19 Ag]

The total of 338 clinical samples (45 positive and 293 negative) confirmed with RT-PCR were tested.

It shows 95.56% PPA (Positive Percent Agreement) and 99.66% NPA (Negative Percent Agreement) shown as below.

[Influenza A]

The total of 338 clinical samples (38 positive and 300 negative) confirmed with RT-PCR were tested.

It shows 100% PPA (Positive Percent Agreement) and 99.67% NPA (Negative Percent Agreement) shown as below.

[Influenza B]

The total of 338 clinical samples (40 positive and 298 negative) confirmed with RT-PCR were tested. 

It shows 97.50% PPA (Positive Percent Agreement) and 98.66% NPA (Negative Percent Agreement) shown as below.

Effective Data Management

Laboratory Information System Connectivity

In the event of a pandemic, the management of a vast amount of clinical result is important. 

However, many laboratories face the challenge in arranging the essential information effectively⁽¹⁾.

The FREND™ System which is LIS compatible provide following features:

Specification

For more information, please visit www.nanoentek.com